Earnings Call Summary | Cytek Biosciences(CTKB.US) Q2 2024 Earnings Conference
Earnings Call Summary | Cytek Biosciences(CTKB.US) Q2 2024 Earnings Conference
The following is a summary of the Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript:
以下是Cytek Biosciences, Inc.（CTKB）2024年第二季度業績會通話摘要:
Financial Performance:
金融業績：
Cytek reported a Q2 revenue of $46.6 million, marking a 4% increase over Q1 and a 6% year-over-year decline.
Service revenue grew 30% from Q2 2023, driven by an expanding installed base.
Adjusted gross profit margin stood at 58% for the quarter, down from 60% year-over-year but up from 55% in Q1.
Full-year revenue guidance was narrowed to $203 million to $210 million, representing a growth of 5% to 9% year-over-year.
Cytek報告Q2營業收入4660萬美元，較Q1增長4％，同比下降6％。
服務收入比2023年第二季度增長30％，這是由於不斷擴大的已安裝基礎。
調整後的毛利潤率季度爲58％，同比下降了60％，但比Q1的55％上升了。
全年營業收入指導範圍縮小至2.03億美元至2.1億美元，同比增長5％至9％。
Business Progress:
業務進展：
This quarter, Cytek expanded its installed base, selling 147 instruments and reaching a total of 2,656 units.
Launched the enhanced small particle detection module (ESP) to improve the capabilities of the Aurora and Northern Light instruments.
Achieved China NMPA approval for one laser and two laser 6-color TBNK reagent cocktails for clinical use.
Service gross margins increased by 8 percentage points year-over-year due to improved productivity.
本季度，Cytek擴大了其已安裝基礎，銷售了147台儀器，總計達到2,656台。
推出增強型小顆粒檢測模塊（ESP）以提高Aurora和Northern Light儀器的功能。
獲得中國NMPA批准用於臨床的一種激光器和兩種激光器6色TBNk試劑組合。
服務毛利率同比增長8個百分點，這是由於提高生產率。
Opportunities:
機會：
The large installed base of conventional flow cytometers presents a significant replacement opportunity with advanced Cytek instruments.
Increased adoption and utilization of Cytek instruments supported by bioinformatics enhancements, such as those in the Cytek Cloud platform and the new spectral panel design tool.
傳統流式細胞儀的大量已安裝基礎爲採用先進的Cytek儀器提供了很大的替換機會。
採用和利用Cytek儀器的增加得到支持，由生物信息學增強，例如在Cytek Cloud平台和新的光譜面板設計工具中的增強。
Risks:
風險：
Continued weakness in the U.S. instrument market, particularly within the academic and government sectors, coupled with elongated sales cycles.
Uncertainties in market conditions that could potentially impact the expected recovery and spending patterns in North America.
美國儀器市場持續疲軟，特別是學術和政府部門，加上銷售週期的延長。
市場條件的不確定性可能會影響北美的預期復甦和支出模式。
More details: Cytek Biosciences IR
更多詳細信息：Cytek Biosciences IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。